{
    "clinical_study": {
        "@rank": "134415", 
        "arm_group": {
            "arm_group_label": "Correlative studies", 
            "description": "Samples are analyzed for SNP profiling using real-time PCR and MLPA."
        }, 
        "brief_summary": {
            "textblock": "This clinical trial studies gene analysis in studying susceptibility to Wilms tumor. Finding\n      genetic markers for Wilms tumor may help identify patients who are at risk of relapse"
        }, 
        "brief_title": "Gene Analysis in Studying Susceptibility to Wilms Tumor", 
        "condition": [
            "Recurrent Wilms Tumor and Other Childhood Kidney Tumors", 
            "Stage I Wilms Tumor", 
            "Stage II Wilms Tumor", 
            "Stage III Wilms Tumor", 
            "Stage IV Wilms Tumor"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Kidney Neoplasms", 
                "Wilms Tumor"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study Subtype: Ancillary/Correlative Observational Study Model: Case-control Time\n      Perspective: Retrospective Biospecimen Retention: Samples With DNA Biospecimen Description:\n      DNA samples Study Population Description: Samples from the National Wilms Tumor Study Group\n      (NWTSG) Sampling Method: Non-Probability Sample\n\n      PRIMARY OBJECTIVES:\n\n      I. To use a genome-wide association analysis to identify novel genetic variants that confer\n      susceptibility to Wilms tumor.\n\n      II. To improve our understanding of the genetic architecture and etiology of Wilms tumor.\n\n      III. To facilitate the identification of genetic markers that are associated with an\n      increased risk of developing of Wilms tumor and/or those at risk of aggressive disease,\n      relapse, additional tumors and/or cancer in their offspring.\n\n      OUTLINE:\n\n      Samples are analyzed for single nucleotide polymorphism (SNP) profiling using real-time\n      polymerase chain reaction (PCR) and multiplex ligation-dependent probe amplification (MLPA)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  3000 samples from the 1958 Birth Cohort (58C) and 3000 from the UK Blood Service\n             control series (NBS)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "We currently have 1300 DNA samples from Wilms tumor cases, primarily from recruitment from\n        oncology clinics over the last decade. We are further identifying Wilms tumor survivors >\n        1000 for targeted recruitment. However, if there is any shortfall, we will use additional\n        US and/or IWTGC cases and we are fully confident that at least 2000 cases for the\n        replication will be available."
            }
        }, 
        "enrollment": {
            "#text": "4000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01808079", 
            "org_study_id": "AREN09B1", 
            "secondary_id": [
                "NCI-2013-00120", 
                "COG-AREN09B1"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Correlative studies", 
            "description": "Correlative studies", 
            "intervention_name": "laboratory biomarker analysis", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Arcadia", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91006-3776"
                }, 
                "name": "Children's Oncology Group"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "OBSERVATIONAL: A Genome-Wide Association Study in Wilms Tumor", 
        "overall_official": {
            "affiliation": "Children's Oncology Group", 
            "last_name": "Paul Grundy", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2100", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Genotype 2000 cases using the Illumina Human660W-Quad BeadChip. This will include 1000 UK cases and 1000 US cases. Genotypes will be compared respectively with existing data from 4500 UK controls and 2000 US controls", 
            "measure": "Use a genome-wide association analysis to identify novel genetic variants that confer susceptibility to Wilms tumor", 
            "safety_issue": "No", 
            "time_frame": "Baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01808079"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Apply methods which increase power to find rare associated variants, for example by looking for extended haplotypes in subsets of the cases.", 
                "measure": "Improve our understanding of the genetic architecture and etiology of Wilms tumor", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "Compare genotype frequencies between cases and controls at each SNP using the Cochran Armitage trend test. We will also undertake genotypic tests. The data will be analyzed individually for the UK/US study populations and combined using analysis adjusting for study group, and related methods which allow for different effects in each population.", 
                "measure": "Facilitate the identification of genetic markers that are associated with an increased risk of developing of Wilms tumor and/or those at risk of aggressive disease, relapse, additional tumors and/or cancer in their offspring.", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }
        ], 
        "source": "Children's Oncology Group", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Children's Oncology Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2009", 
        "study_design": "Observational Model: Case Control, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "March 2013"
    }
}